MannKind (NASDAQ:MNKD - Get Free Report) is projected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect MannKind to post earnings of $0.03 per share and revenue of $74.99 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.
MannKind Price Performance
NASDAQ MNKD traded up $0.11 on Friday, reaching $5.77. The stock had a trading volume of 1,926,239 shares, compared to its average volume of 1,903,410. MannKind has a 1-year low of $3.47 and a 1-year high of $7.63. The company has a market cap of $1.59 billion, a P/E ratio of 82.36 and a beta of 1.28. The firm has a fifty day moving average of $6.06 and a two-hundred day moving average of $6.26.
Wall Street Analyst Weigh In
A number of research firms recently commented on MNKD. StockNews.com cut shares of MannKind from a "buy" rating to a "hold" rating in a research note on Saturday, December 7th. Wedbush started coverage on shares of MannKind in a research report on Monday, February 10th. They issued an "outperform" rating and a $11.00 price target for the company. Wells Fargo & Company assumed coverage on MannKind in a research report on Friday, December 20th. They set an "overweight" rating and a $9.00 price target on the stock. Finally, Royal Bank of Canada raised MannKind from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $7.00 to $10.00 in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $9.21.
Get Our Latest Stock Report on MannKind
MannKind Company Profile
(
Get Free Report)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Further Reading
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
